Physiomics plc announced that it has been awarded a substantial new contract by an existing large pharma client. The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/repair field and will help inform clinical dose and scheduling decisions. The value of the project is £178,000 and it is anticipated that it will be completed over the course of the next six months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 GBX | -13.33% | -13.33% | -18.75% |
May. 03 | Physiomics warns large contracts taken longer than expected | AN |
May. 03 | AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.75% | 2.21M | |
+16.31% | 74.21B | |
-17.43% | 37B | |
+11.58% | 36.86B | |
-8.18% | 28.07B | |
-10.23% | 16.32B | |
+12.17% | 14.97B | |
+8.65% | 10.41B | |
-26.03% | 4.58B | |
-16.92% | 4.3B |
- Stock Market
- Equities
- PYC Stock
- News Physiomics Plc
- Physiomics plc Wins Contract by an Existing Pharma Client